nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Rosuvastatin—atherosclerosis	0.0797	0.211	CbGbCtD
Maraviroc—CYP3A4—Ezetimibe—atherosclerosis	0.0797	0.211	CbGbCtD
Maraviroc—CYP3A4—Simvastatin—atherosclerosis	0.0741	0.196	CbGbCtD
Maraviroc—CYP3A4—Pravastatin—atherosclerosis	0.0725	0.192	CbGbCtD
Maraviroc—CYP3A4—Lovastatin—atherosclerosis	0.0725	0.192	CbGbCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00142	0.00617	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—KNG1—atherosclerosis	0.00141	0.00612	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGTR1—atherosclerosis	0.0014	0.00608	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CCR2—atherosclerosis	0.00139	0.00603	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL4—atherosclerosis	0.00136	0.00591	CbGpPWpGaD
Maraviroc—CYP3A4—Farnesoid X Receptor  Pathway—CYP7A1—atherosclerosis	0.00134	0.0058	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT3—atherosclerosis	0.0013	0.00563	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	0.00129	0.0056	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.00129	0.0056	CbGpPWpGaD
Maraviroc—CYP3A4—Aflatoxin B1 metabolism—GSTM1—atherosclerosis	0.00123	0.00533	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00122	0.0053	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—UTS2—atherosclerosis	0.00121	0.00527	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—KNG1—atherosclerosis	0.00119	0.00516	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—EDN1—atherosclerosis	0.00119	0.00515	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL5—atherosclerosis	0.00118	0.00512	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CX3CR1—atherosclerosis	0.00116	0.00505	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CASR—atherosclerosis	0.00116	0.00505	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CX3CL1—atherosclerosis	0.00114	0.00495	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL1B—atherosclerosis	0.00112	0.00486	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00111	0.00285	CcSEcCtD
Maraviroc—Eosinophilia—Lovastatin—atherosclerosis	0.00111	0.00283	CcSEcCtD
Maraviroc—Sinusitis—Rosuvastatin—atherosclerosis	0.00111	0.00282	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.0011	0.0048	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.0011	0.0048	CbGpPWpGaD
Maraviroc—Influenza—Ezetimibe—atherosclerosis	0.0011	0.00281	CcSEcCtD
Maraviroc—Pancreatitis—Lovastatin—atherosclerosis	0.0011	0.00281	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.0011	0.00476	CbGpPWpGaD
Maraviroc—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00109	0.00279	CcSEcCtD
Maraviroc—Eosinophilia—Ezetimibe—atherosclerosis	0.00109	0.00278	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CNR2—atherosclerosis	0.00108	0.0047	CbGpPWpGaD
Maraviroc—Pancreatitis—Ezetimibe—atherosclerosis	0.00108	0.00275	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.00108	0.00467	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—HRH1—atherosclerosis	0.00106	0.00462	CbGpPWpGaD
Maraviroc—Rhinitis—Rosuvastatin—atherosclerosis	0.00106	0.00271	CcSEcCtD
Maraviroc—Pharyngitis—Rosuvastatin—atherosclerosis	0.00105	0.00268	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—NFKB1—atherosclerosis	0.00104	0.00453	CbGpPWpGaD
Maraviroc—Eosinophilia—Simvastatin—atherosclerosis	0.00104	0.00265	CcSEcCtD
Maraviroc—Pancreatitis—Simvastatin—atherosclerosis	0.00103	0.00262	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK8—atherosclerosis	0.00103	0.00446	CbGpPWpGaD
Maraviroc—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00102	0.00261	CcSEcCtD
Maraviroc—Orthostatic hypotension—Niacin—atherosclerosis	0.00102	0.0026	CcSEcCtD
Maraviroc—Bronchitis—Simvastatin—atherosclerosis	0.00101	0.00257	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—CCL5—atherosclerosis	0.000993	0.00432	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.00099	0.00253	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000987	0.00252	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGT—atherosclerosis	0.000985	0.00428	CbGpPWpGaD
Maraviroc—Nasopharyngitis—Pravastatin—atherosclerosis	0.00098	0.0025	CcSEcCtD
Maraviroc—Infestation—Ezetimibe—atherosclerosis	0.000979	0.0025	CcSEcCtD
Maraviroc—Infestation NOS—Ezetimibe—atherosclerosis	0.000979	0.0025	CcSEcCtD
Maraviroc—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000979	0.0025	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000974	0.00249	CcSEcCtD
Maraviroc—Abdominal distension—Niacin—atherosclerosis	0.000968	0.00247	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000967	0.00247	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—HRH1—atherosclerosis	0.000966	0.0042	CbGpPWpGaD
Maraviroc—Influenza—Niacin—atherosclerosis	0.000962	0.00246	CcSEcCtD
Maraviroc—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00096	0.00245	CcSEcCtD
Maraviroc—Jaundice—Ezetimibe—atherosclerosis	0.000955	0.00244	CcSEcCtD
Maraviroc—Abdominal distension—Pravastatin—atherosclerosis	0.000953	0.00244	CcSEcCtD
Maraviroc—Influenza—Pravastatin—atherosclerosis	0.000947	0.00242	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000945	0.0041	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000939	0.00408	CbGpPWpGaD
Maraviroc—Eosinophilia—Pravastatin—atherosclerosis	0.000938	0.0024	CcSEcCtD
Maraviroc—Angina pectoris—Niacin—atherosclerosis	0.000937	0.00239	CcSEcCtD
Maraviroc—Sinusitis—Lovastatin—atherosclerosis	0.000937	0.00239	CcSEcCtD
Maraviroc—Depression—Simvastatin—atherosclerosis	0.000931	0.00238	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CCL3—atherosclerosis	0.00093	0.00404	CbGpPWpGaD
Maraviroc—Pancreatitis—Pravastatin—atherosclerosis	0.000929	0.00237	CcSEcCtD
Maraviroc—Mental disorder—Rosuvastatin—atherosclerosis	0.000927	0.00237	CcSEcCtD
Maraviroc—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000926	0.00237	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000926	0.00237	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG1—atherosclerosis	0.000925	0.00402	CbGpPWpGaD
Maraviroc—Bronchitis—Niacin—atherosclerosis	0.000925	0.00236	CcSEcCtD
Maraviroc—Angina pectoris—Pravastatin—atherosclerosis	0.000923	0.00236	CcSEcCtD
Maraviroc—Sinusitis—Ezetimibe—atherosclerosis	0.000919	0.00235	CcSEcCtD
Maraviroc—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000916	0.00234	CcSEcCtD
Maraviroc—Jaundice—Simvastatin—atherosclerosis	0.00091	0.00233	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—F2—atherosclerosis	0.00091	0.00395	CbGpPWpGaD
Maraviroc—Flatulence—Rosuvastatin—atherosclerosis	0.000907	0.00232	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK3—atherosclerosis	0.000896	0.00389	CbGpPWpGaD
Maraviroc—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00088	0.00225	CcSEcCtD
Maraviroc—Sinusitis—Simvastatin—atherosclerosis	0.000876	0.00224	CcSEcCtD
Maraviroc—Pharyngitis—Ezetimibe—atherosclerosis	0.000873	0.00223	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—TGFB1—atherosclerosis	0.000869	0.00378	CbGpPWpGaD
Maraviroc—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000864	0.00221	CcSEcCtD
Maraviroc—Erythema multiforme—Lovastatin—atherosclerosis	0.000848	0.00217	CcSEcCtD
Maraviroc—Depression—Pravastatin—atherosclerosis	0.000842	0.00215	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CCR2—atherosclerosis	0.000841	0.00365	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—EDNRA—atherosclerosis	0.000841	0.00365	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP7A1—atherosclerosis	0.000839	0.00364	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000837	0.00214	CcSEcCtD
Maraviroc—Stomatitis—Niacin—atherosclerosis	0.000836	0.00214	CcSEcCtD
Maraviroc—Jaundice—Niacin—atherosclerosis	0.000836	0.00214	CcSEcCtD
Maraviroc—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000832	0.00213	CcSEcCtD
Maraviroc—Erythema multiforme—Ezetimibe—atherosclerosis	0.000831	0.00212	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—AGT—atherosclerosis	0.000831	0.00361	CbGpPWpGaD
Maraviroc—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000828	0.00212	CcSEcCtD
Maraviroc—Myocardial infarction—Pravastatin—atherosclerosis	0.000828	0.00212	CcSEcCtD
Maraviroc—Jaundice—Pravastatin—atherosclerosis	0.000823	0.0021	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—GHRL—atherosclerosis	0.000819	0.00356	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.000811	0.00352	CbGpPWpGaD
Maraviroc—Cough—Rosuvastatin—atherosclerosis	0.000804	0.00205	CcSEcCtD
Maraviroc—Angiopathy—Ezetimibe—atherosclerosis	0.000798	0.00204	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000796	0.00346	CbGpPWpGaD
Maraviroc—Erythema multiforme—Simvastatin—atherosclerosis	0.000793	0.00203	CcSEcCtD
Maraviroc—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000792	0.00202	CcSEcCtD
Maraviroc—Sinusitis—Pravastatin—atherosclerosis	0.000792	0.00202	CcSEcCtD
Maraviroc—Alopecia—Lovastatin—atherosclerosis	0.000792	0.00202	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.00079	0.00343	CbGpPWpGaD
Maraviroc—Myalgia—Rosuvastatin—atherosclerosis	0.000784	0.002	CcSEcCtD
Maraviroc—Alopecia—Ezetimibe—atherosclerosis	0.000777	0.00199	CcSEcCtD
Maraviroc—Rhinitis—Niacin—atherosclerosis	0.000772	0.00197	CcSEcCtD
Maraviroc—Mental disorder—Ezetimibe—atherosclerosis	0.00077	0.00197	CcSEcCtD
Maraviroc—Flatulence—Lovastatin—atherosclerosis	0.000769	0.00196	CcSEcCtD
Maraviroc—Erythema—Ezetimibe—atherosclerosis	0.000765	0.00196	CcSEcCtD
Maraviroc—Malnutrition—Ezetimibe—atherosclerosis	0.000765	0.00196	CcSEcCtD
Maraviroc—Rhinitis—Pravastatin—atherosclerosis	0.00076	0.00194	CcSEcCtD
Maraviroc—Flatulence—Ezetimibe—atherosclerosis	0.000754	0.00193	CcSEcCtD
Maraviroc—Pharyngitis—Pravastatin—atherosclerosis	0.000752	0.00192	CcSEcCtD
Maraviroc—Infection—Rosuvastatin—atherosclerosis	0.000747	0.00191	CcSEcCtD
Maraviroc—Alopecia—Simvastatin—atherosclerosis	0.000741	0.00189	CcSEcCtD
Maraviroc—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000737	0.00188	CcSEcCtD
Maraviroc—Mental disorder—Simvastatin—atherosclerosis	0.000735	0.00188	CcSEcCtD
Maraviroc—Tremor—Lovastatin—atherosclerosis	0.000731	0.00187	CcSEcCtD
Maraviroc—Erythema—Simvastatin—atherosclerosis	0.00073	0.00187	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—atherosclerosis	0.000726	0.00315	CbGpPWpGaD
Maraviroc—Eye disorder—Niacin—atherosclerosis	0.00072	0.00184	CcSEcCtD
Maraviroc—Flatulence—Simvastatin—atherosclerosis	0.000719	0.00184	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—KNG1—atherosclerosis	0.000719	0.00312	CbGpPWpGaD
Maraviroc—Erythema multiforme—Pravastatin—atherosclerosis	0.000717	0.00183	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—AGTR1—atherosclerosis	0.000715	0.00311	CbGpPWpGaD
Maraviroc—Anaemia—Ezetimibe—atherosclerosis	0.000707	0.00181	CcSEcCtD
Maraviroc—Cardiac disorder—Pravastatin—atherosclerosis	0.000704	0.0018	CcSEcCtD
Maraviroc—Angiopathy—Niacin—atherosclerosis	0.000699	0.00178	CcSEcCtD
Maraviroc—Leukopenia—Lovastatin—atherosclerosis	0.000699	0.00178	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCL4—atherosclerosis	0.000698	0.00303	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—UTS2—atherosclerosis	0.000686	0.00298	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000685	0.00175	CcSEcCtD
Maraviroc—Tremor—Simvastatin—atherosclerosis	0.000684	0.00175	CcSEcCtD
Maraviroc—Alopecia—Niacin—atherosclerosis	0.00068	0.00174	CcSEcCtD
Maraviroc—Insomnia—Rosuvastatin—atherosclerosis	0.00068	0.00174	CcSEcCtD
Maraviroc—Paraesthesia—Rosuvastatin—atherosclerosis	0.000675	0.00172	CcSEcCtD
Maraviroc—Anaemia—Simvastatin—atherosclerosis	0.000675	0.00172	CcSEcCtD
Maraviroc—Malnutrition—Niacin—atherosclerosis	0.00067	0.00171	CcSEcCtD
Maraviroc—Erythema—Niacin—atherosclerosis	0.00067	0.00171	CcSEcCtD
Maraviroc—Alopecia—Pravastatin—atherosclerosis	0.00067	0.00171	CcSEcCtD
Maraviroc—Cough—Ezetimibe—atherosclerosis	0.000668	0.00171	CcSEcCtD
Maraviroc—Myalgia—Lovastatin—atherosclerosis	0.000664	0.0017	CcSEcCtD
Maraviroc—Anxiety—Lovastatin—atherosclerosis	0.000662	0.00169	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000661	0.00287	CbGpPWpGaD
Maraviroc—Flatulence—Niacin—atherosclerosis	0.00066	0.00169	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CASR—atherosclerosis	0.000657	0.00286	CbGpPWpGaD
Maraviroc—Discomfort—Lovastatin—atherosclerosis	0.000656	0.00168	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—IL6—atherosclerosis	0.000655	0.00285	CbGpPWpGaD
Maraviroc—Leukopenia—Simvastatin—atherosclerosis	0.000653	0.00167	CcSEcCtD
Maraviroc—Myalgia—Ezetimibe—atherosclerosis	0.000652	0.00167	CcSEcCtD
Maraviroc—Flatulence—Pravastatin—atherosclerosis	0.00065	0.00166	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000647	0.00165	CcSEcCtD
Maraviroc—Discomfort—Ezetimibe—atherosclerosis	0.000644	0.00165	CcSEcCtD
Maraviroc—Pain—Rosuvastatin—atherosclerosis	0.000643	0.00164	CcSEcCtD
Maraviroc—Constipation—Rosuvastatin—atherosclerosis	0.000643	0.00164	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.000641	0.00279	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOA4—atherosclerosis	0.00064	0.00278	CbGpPWpGaD
Maraviroc—Infection—Lovastatin—atherosclerosis	0.000633	0.00162	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—UTS2—atherosclerosis	0.000623	0.0027	CbGpPWpGaD
Maraviroc—Myalgia—Simvastatin—atherosclerosis	0.000621	0.00159	CcSEcCtD
Maraviroc—Infection—Ezetimibe—atherosclerosis	0.000621	0.00159	CcSEcCtD
Maraviroc—Anxiety—Simvastatin—atherosclerosis	0.000619	0.00158	CcSEcCtD
Maraviroc—Tremor—Pravastatin—atherosclerosis	0.000618	0.00158	CcSEcCtD
Maraviroc—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000615	0.00157	CcSEcCtD
Maraviroc—Discomfort—Simvastatin—atherosclerosis	0.000614	0.00157	CcSEcCtD
Maraviroc—Nervous system disorder—Ezetimibe—atherosclerosis	0.000613	0.00157	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CNR2—atherosclerosis	0.000611	0.00265	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00061	0.00265	CbGpPWpGaD
Maraviroc—Anaemia—Pravastatin—atherosclerosis	0.00061	0.00156	CcSEcCtD
Maraviroc—Anorexia—Lovastatin—atherosclerosis	0.000607	0.00155	CcSEcCtD
Maraviroc—Skin disorder—Ezetimibe—atherosclerosis	0.000607	0.00155	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—EDN1—atherosclerosis	0.000606	0.00263	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—AKT1—atherosclerosis	0.000604	0.00262	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL5—atherosclerosis	0.000601	0.00261	CbGpPWpGaD
Maraviroc—Syncope—Niacin—atherosclerosis	0.000601	0.00154	CcSEcCtD
Maraviroc—Leukopenia—Niacin—atherosclerosis	0.0006	0.00153	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CX3CR1—atherosclerosis	0.000597	0.00259	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CASR—atherosclerosis	0.000597	0.00259	CbGpPWpGaD
Maraviroc—Oedema—Simvastatin—atherosclerosis	0.000596	0.00152	CcSEcCtD
Maraviroc—Abdominal pain—Rosuvastatin—atherosclerosis	0.000594	0.00152	CcSEcCtD
Maraviroc—Infection—Simvastatin—atherosclerosis	0.000592	0.00151	CcSEcCtD
Maraviroc—Leukopenia—Pravastatin—atherosclerosis	0.000591	0.00151	CcSEcCtD
Maraviroc—Loss of consciousness—Niacin—atherosclerosis	0.000589	0.00151	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CX3CL1—atherosclerosis	0.000585	0.00254	CbGpPWpGaD
Maraviroc—Cough—Niacin—atherosclerosis	0.000585	0.00149	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00058	0.00148	CcSEcCtD
Maraviroc—Insomnia—Lovastatin—atherosclerosis	0.000576	0.00147	CcSEcCtD
Maraviroc—CYP3A4—Estrogen metabolism—GSTM1—atherosclerosis	0.000576	0.0025	CbGpPWpGaD
Maraviroc—Cough—Pravastatin—atherosclerosis	0.000576	0.00147	CcSEcCtD
Maraviroc—Paraesthesia—Lovastatin—atherosclerosis	0.000572	0.00146	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HRH1—atherosclerosis	0.000571	0.00248	CbGpPWpGaD
Maraviroc—Myalgia—Niacin—atherosclerosis	0.000571	0.00146	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000569	0.00145	CcSEcCtD
Maraviroc—Anorexia—Simvastatin—atherosclerosis	0.000568	0.00145	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000567	0.00145	CcSEcCtD
Maraviroc—Insomnia—Ezetimibe—atherosclerosis	0.000565	0.00144	CcSEcCtD
Maraviroc—Myalgia—Pravastatin—atherosclerosis	0.000562	0.00144	CcSEcCtD
Maraviroc—Paraesthesia—Ezetimibe—atherosclerosis	0.000561	0.00143	CcSEcCtD
Maraviroc—Anxiety—Pravastatin—atherosclerosis	0.00056	0.00143	CcSEcCtD
Maraviroc—Discomfort—Pravastatin—atherosclerosis	0.000555	0.00142	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CNR2—atherosclerosis	0.000555	0.00241	CbGpPWpGaD
Maraviroc—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000554	0.00141	CcSEcCtD
Maraviroc—Decreased appetite—Lovastatin—atherosclerosis	0.000554	0.00141	CcSEcCtD
Maraviroc—CCR5—Disease—APOA2—atherosclerosis	0.000551	0.00239	CbGpPWpGaD
Maraviroc—Fatigue—Lovastatin—atherosclerosis	0.000549	0.0014	CcSEcCtD
Maraviroc—Oedema—Niacin—atherosclerosis	0.000547	0.0014	CcSEcCtD
Maraviroc—Constipation—Lovastatin—atherosclerosis	0.000545	0.00139	CcSEcCtD
Maraviroc—Pain—Lovastatin—atherosclerosis	0.000545	0.00139	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000544	0.00236	CbGpPWpGaD
Maraviroc—Decreased appetite—Ezetimibe—atherosclerosis	0.000543	0.00139	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000543	0.00139	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL8—atherosclerosis	0.000541	0.00235	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000539	0.00138	CcSEcCtD
Maraviroc—Asthenia—Rosuvastatin—atherosclerosis	0.000539	0.00138	CcSEcCtD
Maraviroc—Insomnia—Simvastatin—atherosclerosis	0.000539	0.00138	CcSEcCtD
Maraviroc—Oedema—Pravastatin—atherosclerosis	0.000539	0.00138	CcSEcCtD
Maraviroc—Fatigue—Ezetimibe—atherosclerosis	0.000539	0.00138	CcSEcCtD
Maraviroc—Shock—Niacin—atherosclerosis	0.000538	0.00138	CcSEcCtD
Maraviroc—Infection—Pravastatin—atherosclerosis	0.000535	0.00137	CcSEcCtD
Maraviroc—Paraesthesia—Simvastatin—atherosclerosis	0.000535	0.00137	CcSEcCtD
Maraviroc—Pain—Ezetimibe—atherosclerosis	0.000534	0.00137	CcSEcCtD
Maraviroc—Constipation—Ezetimibe—atherosclerosis	0.000534	0.00137	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7A1—atherosclerosis	0.000533	0.00231	CbGpPWpGaD
Maraviroc—Pruritus—Rosuvastatin—atherosclerosis	0.000532	0.00136	CcSEcCtD
Maraviroc—Skin disorder—Niacin—atherosclerosis	0.000531	0.00136	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP7A1—atherosclerosis	0.000526	0.00228	CbGpPWpGaD
Maraviroc—Anorexia—Niacin—atherosclerosis	0.000521	0.00133	CcSEcCtD
Maraviroc—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000521	0.00133	CcSEcCtD
Maraviroc—Decreased appetite—Simvastatin—atherosclerosis	0.000518	0.00132	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000514	0.00131	CcSEcCtD
Maraviroc—Diarrhoea—Rosuvastatin—atherosclerosis	0.000514	0.00131	CcSEcCtD
Maraviroc—Fatigue—Simvastatin—atherosclerosis	0.000514	0.00131	CcSEcCtD
Maraviroc—Anorexia—Pravastatin—atherosclerosis	0.000513	0.00131	CcSEcCtD
Maraviroc—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000511	0.00131	CcSEcCtD
Maraviroc—Pain—Simvastatin—atherosclerosis	0.000509	0.0013	CcSEcCtD
Maraviroc—Constipation—Simvastatin—atherosclerosis	0.000509	0.0013	CcSEcCtD
Maraviroc—CCR5—Disease—BGN—atherosclerosis	0.000509	0.00221	CbGpPWpGaD
Maraviroc—Body temperature increased—Lovastatin—atherosclerosis	0.000503	0.00129	CcSEcCtD
Maraviroc—Abdominal pain—Lovastatin—atherosclerosis	0.000503	0.00129	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—AGT—atherosclerosis	0.000503	0.00219	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000498	0.00127	CcSEcCtD
Maraviroc—Dizziness—Rosuvastatin—atherosclerosis	0.000497	0.00127	CcSEcCtD
Maraviroc—Insomnia—Niacin—atherosclerosis	0.000495	0.00126	CcSEcCtD
Maraviroc—Abdominal pain—Ezetimibe—atherosclerosis	0.000494	0.00126	CcSEcCtD
Maraviroc—Body temperature increased—Ezetimibe—atherosclerosis	0.000494	0.00126	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—atherosclerosis	0.000492	0.00214	CbGpPWpGaD
Maraviroc—Paraesthesia—Niacin—atherosclerosis	0.000491	0.00126	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000491	0.00125	CcSEcCtD
Maraviroc—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000487	0.00124	CcSEcCtD
Maraviroc—Insomnia—Pravastatin—atherosclerosis	0.000487	0.00124	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—atherosclerosis	0.000486	0.00211	CbGpPWpGaD
Maraviroc—Paraesthesia—Pravastatin—atherosclerosis	0.000484	0.00124	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCL3—atherosclerosis	0.000477	0.00207	CbGpPWpGaD
Maraviroc—Decreased appetite—Niacin—atherosclerosis	0.000476	0.00122	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—EDNRA—atherosclerosis	0.000475	0.00206	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCR2—atherosclerosis	0.000475	0.00206	CbGpPWpGaD
Maraviroc—Rash—Rosuvastatin—atherosclerosis	0.000474	0.00121	CcSEcCtD
Maraviroc—Dermatitis—Rosuvastatin—atherosclerosis	0.000473	0.00121	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Niacin—atherosclerosis	0.000472	0.00121	CcSEcCtD
Maraviroc—Body temperature increased—Simvastatin—atherosclerosis	0.000471	0.0012	CcSEcCtD
Maraviroc—Abdominal pain—Simvastatin—atherosclerosis	0.000471	0.0012	CcSEcCtD
Maraviroc—Headache—Rosuvastatin—atherosclerosis	0.000471	0.0012	CcSEcCtD
Maraviroc—Hypersensitivity—Lovastatin—atherosclerosis	0.000469	0.0012	CcSEcCtD
Maraviroc—Decreased appetite—Pravastatin—atherosclerosis	0.000468	0.0012	CcSEcCtD
Maraviroc—Pain—Niacin—atherosclerosis	0.000468	0.0012	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—F2—atherosclerosis	0.000465	0.00202	CbGpPWpGaD
Maraviroc—Fatigue—Pravastatin—atherosclerosis	0.000464	0.00119	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—GHRL—atherosclerosis	0.000463	0.00201	CbGpPWpGaD
Maraviroc—Constipation—Pravastatin—atherosclerosis	0.000461	0.00118	CcSEcCtD
Maraviroc—Pain—Pravastatin—atherosclerosis	0.000461	0.00118	CcSEcCtD
Maraviroc—Hypersensitivity—Ezetimibe—atherosclerosis	0.00046	0.00118	CcSEcCtD
Maraviroc—Asthenia—Lovastatin—atherosclerosis	0.000457	0.00117	CcSEcCtD
Maraviroc—Pruritus—Lovastatin—atherosclerosis	0.000451	0.00115	CcSEcCtD
Maraviroc—Asthenia—Ezetimibe—atherosclerosis	0.000448	0.00115	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APOA4—atherosclerosis	0.000448	0.00195	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Niacin—atherosclerosis	0.000447	0.00114	CcSEcCtD
Maraviroc—Nausea—Rosuvastatin—atherosclerosis	0.000446	0.00114	CcSEcCtD
Maraviroc—CCR5—Disease—CST3—atherosclerosis	0.000443	0.00193	CbGpPWpGaD
Maraviroc—Pruritus—Ezetimibe—atherosclerosis	0.000442	0.00113	CcSEcCtD
Maraviroc—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00044	0.00113	CcSEcCtD
Maraviroc—Hypersensitivity—Simvastatin—atherosclerosis	0.000439	0.00112	CcSEcCtD
Maraviroc—Diarrhoea—Lovastatin—atherosclerosis	0.000436	0.00111	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.000433	0.00188	CbGpPWpGaD
Maraviroc—Body temperature increased—Niacin—atherosclerosis	0.000432	0.0011	CcSEcCtD
Maraviroc—Abdominal pain—Niacin—atherosclerosis	0.000432	0.0011	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.000432	0.00188	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCR2—atherosclerosis	0.000432	0.00187	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EDNRA—atherosclerosis	0.000432	0.00187	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.00043	0.00187	CbGpPWpGaD
Maraviroc—Asthenia—Simvastatin—atherosclerosis	0.000427	0.00109	CcSEcCtD
Maraviroc—Diarrhoea—Ezetimibe—atherosclerosis	0.000427	0.00109	CcSEcCtD
Maraviroc—Body temperature increased—Pravastatin—atherosclerosis	0.000426	0.00109	CcSEcCtD
Maraviroc—Abdominal pain—Pravastatin—atherosclerosis	0.000426	0.00109	CcSEcCtD
Maraviroc—Pruritus—Simvastatin—atherosclerosis	0.000421	0.00108	CcSEcCtD
Maraviroc—Dizziness—Lovastatin—atherosclerosis	0.000421	0.00108	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—GHRL—atherosclerosis	0.000421	0.00183	CbGpPWpGaD
Maraviroc—CCR5—Disease—NAMPT—atherosclerosis	0.00042	0.00182	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOC3—atherosclerosis	0.000415	0.0018	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL2—atherosclerosis	0.000414	0.0018	CbGpPWpGaD
Maraviroc—Dizziness—Ezetimibe—atherosclerosis	0.000413	0.00106	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCL4—atherosclerosis	0.000413	0.00179	CbGpPWpGaD
Maraviroc—CCR5—Disease—LDLR—atherosclerosis	0.000412	0.00179	CbGpPWpGaD
Maraviroc—Diarrhoea—Simvastatin—atherosclerosis	0.000408	0.00104	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—KNG1—atherosclerosis	0.000406	0.00177	CbGpPWpGaD
Maraviroc—Vomiting—Lovastatin—atherosclerosis	0.000405	0.00103	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AGTR1—atherosclerosis	0.000404	0.00176	CbGpPWpGaD
Maraviroc—Hypersensitivity—Niacin—atherosclerosis	0.000403	0.00103	CcSEcCtD
Maraviroc—Rash—Lovastatin—atherosclerosis	0.000402	0.00103	CcSEcCtD
Maraviroc—Dermatitis—Lovastatin—atherosclerosis	0.000401	0.00103	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.000399	0.00173	CbGpPWpGaD
Maraviroc—Headache—Lovastatin—atherosclerosis	0.000399	0.00102	CcSEcCtD
Maraviroc—CCR5—Disease—HSPA1B—atherosclerosis	0.000398	0.00173	CbGpPWpGaD
Maraviroc—Vomiting—Ezetimibe—atherosclerosis	0.000397	0.00101	CcSEcCtD
Maraviroc—Hypersensitivity—Pravastatin—atherosclerosis	0.000397	0.00101	CcSEcCtD
Maraviroc—Dizziness—Simvastatin—atherosclerosis	0.000394	0.00101	CcSEcCtD
Maraviroc—Rash—Ezetimibe—atherosclerosis	0.000394	0.00101	CcSEcCtD
Maraviroc—Dermatitis—Ezetimibe—atherosclerosis	0.000394	0.00101	CcSEcCtD
Maraviroc—Asthenia—Niacin—atherosclerosis	0.000392	0.001	CcSEcCtD
Maraviroc—Headache—Ezetimibe—atherosclerosis	0.000391	0.001	CcSEcCtD
Maraviroc—Pruritus—Niacin—atherosclerosis	0.000387	0.000989	CcSEcCtD
Maraviroc—Asthenia—Pravastatin—atherosclerosis	0.000386	0.000987	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APOA2—atherosclerosis	0.000386	0.00167	CbGpPWpGaD
Maraviroc—CCR5—Disease—NCF1—atherosclerosis	0.000385	0.00167	CbGpPWpGaD
Maraviroc—Pruritus—Pravastatin—atherosclerosis	0.000381	0.000974	CcSEcCtD
Maraviroc—Vomiting—Simvastatin—atherosclerosis	0.000379	0.000968	CcSEcCtD
Maraviroc—Nausea—Lovastatin—atherosclerosis	0.000378	0.000967	CcSEcCtD
Maraviroc—Rash—Simvastatin—atherosclerosis	0.000376	0.00096	CcSEcCtD
Maraviroc—Dermatitis—Simvastatin—atherosclerosis	0.000375	0.000959	CcSEcCtD
Maraviroc—Diarrhoea—Niacin—atherosclerosis	0.000374	0.000956	CcSEcCtD
Maraviroc—Headache—Simvastatin—atherosclerosis	0.000373	0.000954	CcSEcCtD
Maraviroc—Nausea—Ezetimibe—atherosclerosis	0.000371	0.000948	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KNG1—atherosclerosis	0.000369	0.0016	CbGpPWpGaD
Maraviroc—Diarrhoea—Pravastatin—atherosclerosis	0.000369	0.000942	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—UTS2—atherosclerosis	0.000368	0.0016	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AGTR1—atherosclerosis	0.000367	0.00159	CbGpPWpGaD
Maraviroc—CCR5—Disease—CYBA—atherosclerosis	0.000362	0.00157	CbGpPWpGaD
Maraviroc—Dizziness—Niacin—atherosclerosis	0.000362	0.000924	CcSEcCtD
Maraviroc—Dizziness—Pravastatin—atherosclerosis	0.000356	0.00091	CcSEcCtD
Maraviroc—CCR5—Disease—PARP1—atherosclerosis	0.000355	0.00154	CbGpPWpGaD
Maraviroc—Nausea—Simvastatin—atherosclerosis	0.000354	0.000904	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CX3CR1—atherosclerosis	0.000353	0.00153	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASR—atherosclerosis	0.000353	0.00153	CbGpPWpGaD
Maraviroc—Vomiting—Niacin—atherosclerosis	0.000348	0.000889	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CX3CL1—atherosclerosis	0.000346	0.0015	CbGpPWpGaD
Maraviroc—Rash—Niacin—atherosclerosis	0.000345	0.000881	CcSEcCtD
Maraviroc—Dermatitis—Niacin—atherosclerosis	0.000345	0.000881	CcSEcCtD
Maraviroc—Headache—Niacin—atherosclerosis	0.000343	0.000876	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—EDN1—atherosclerosis	0.000343	0.00149	CbGpPWpGaD
Maraviroc—Vomiting—Pravastatin—atherosclerosis	0.000342	0.000875	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CCL5—atherosclerosis	0.00034	0.00148	CbGpPWpGaD
Maraviroc—Rash—Pravastatin—atherosclerosis	0.00034	0.000868	CcSEcCtD
Maraviroc—Dermatitis—Pravastatin—atherosclerosis	0.000339	0.000867	CcSEcCtD
Maraviroc—Headache—Pravastatin—atherosclerosis	0.000337	0.000862	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CNR2—atherosclerosis	0.000328	0.00142	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL8—atherosclerosis	0.000328	0.00142	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MMP3—atherosclerosis	0.000327	0.00142	CbGpPWpGaD
Maraviroc—Nausea—Niacin—atherosclerosis	0.000325	0.00083	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PRKCG—atherosclerosis	0.000323	0.0014	CbGpPWpGaD
Maraviroc—Nausea—Pravastatin—atherosclerosis	0.00032	0.000817	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EDN1—atherosclerosis	0.000311	0.00135	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL5—atherosclerosis	0.000309	0.00134	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.0003	0.0013	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PRKCG—atherosclerosis	0.000293	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VWF—atherosclerosis	0.000292	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOC3—atherosclerosis	0.00029	0.00126	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LDLR—atherosclerosis	0.000289	0.00125	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AGT—atherosclerosis	0.000284	0.00124	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL3—atherosclerosis	0.000282	0.00122	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NCF1—atherosclerosis	0.00027	0.00117	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOB—atherosclerosis	0.000267	0.00116	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—F2—atherosclerosis	0.000263	0.00114	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AGT—atherosclerosis	0.000258	0.00112	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDNRA—atherosclerosis	0.000255	0.00111	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCR2—atherosclerosis	0.000255	0.00111	CbGpPWpGaD
Maraviroc—CCR5—Disease—LPL—atherosclerosis	0.000255	0.00111	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CYBA—atherosclerosis	0.000254	0.0011	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000251	0.00109	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLAT—atherosclerosis	0.000248	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PARP1—atherosclerosis	0.000248	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GHRL—atherosclerosis	0.000248	0.00108	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	0.000248	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Disease—PRKCG—atherosclerosis	0.000248	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—F2—atherosclerosis	0.000239	0.00104	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP7A1—atherosclerosis	0.000229	0.000996	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTHFR—atherosclerosis	0.000229	0.000996	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—atherosclerosis	0.000228	0.000992	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP7A1—atherosclerosis	0.000226	0.000982	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFB—atherosclerosis	0.000223	0.000969	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KNG1—atherosclerosis	0.000218	0.000947	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGTR1—atherosclerosis	0.000217	0.000942	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOE—atherosclerosis	0.000213	0.000927	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL2—atherosclerosis	0.000213	0.000924	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP27A1—atherosclerosis	0.000212	0.000921	CbGpPWpGaD
Maraviroc—CCR5—Disease—CAV1—atherosclerosis	0.000211	0.000919	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLG—atherosclerosis	0.000211	0.000918	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOA1—atherosclerosis	0.000211	0.000916	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP27A1—atherosclerosis	0.000209	0.000908	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SOCS3—atherosclerosis	0.0002	0.000869	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS2—atherosclerosis	0.000199	0.000864	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP3—atherosclerosis	0.000193	0.000839	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF2—atherosclerosis	0.000192	0.000836	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOB—atherosclerosis	0.000187	0.000811	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—atherosclerosis	0.000185	0.000804	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDN1—atherosclerosis	0.000184	0.000798	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL5—atherosclerosis	0.000182	0.000792	CbGpPWpGaD
Maraviroc—CCR5—Disease—INS—atherosclerosis	0.000182	0.000792	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LPL—atherosclerosis	0.000178	0.000774	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRKCG—atherosclerosis	0.000173	0.000753	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPP1—atherosclerosis	0.000169	0.000734	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—atherosclerosis	0.000168	0.00073	CbGpPWpGaD
Maraviroc—CCR5—Disease—SERPINE1—atherosclerosis	0.000167	0.000727	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS3—atherosclerosis	0.00016	0.000695	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFB—atherosclerosis	0.000156	0.000679	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGT—atherosclerosis	0.000153	0.000663	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LEP—atherosclerosis	0.000149	0.000649	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOE—atherosclerosis	0.000149	0.000649	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CAV1—atherosclerosis	0.000148	0.000643	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOA1—atherosclerosis	0.000148	0.000642	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—atherosclerosis	0.000146	0.000635	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ESR1—atherosclerosis	0.000143	0.00062	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—F2—atherosclerosis	0.000141	0.000612	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—atherosclerosis	0.000135	0.000586	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—atherosclerosis	0.000129	0.000561	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—INS—atherosclerosis	0.000128	0.000555	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL2—atherosclerosis	0.000126	0.000546	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF1—atherosclerosis	0.000123	0.000536	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SERPINE1—atherosclerosis	0.000117	0.000509	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—atherosclerosis	0.000114	0.000495	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOS3—atherosclerosis	0.000112	0.000486	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK3—atherosclerosis	0.000109	0.000473	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—atherosclerosis	0.000106	0.000459	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL8—atherosclerosis	9.93e-05	0.000431	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—atherosclerosis	9.59e-05	0.000417	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	9.47e-05	0.000411	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—atherosclerosis	9.44e-05	0.00041	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	9.34e-05	0.000406	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—atherosclerosis	8.98e-05	0.00039	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NFKB1—atherosclerosis	8.89e-05	0.000386	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK8—atherosclerosis	8.74e-05	0.000379	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—atherosclerosis	8.71e-05	0.000378	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—atherosclerosis	8.07e-05	0.00035	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT3—atherosclerosis	7.99e-05	0.000347	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—atherosclerosis	7.97e-05	0.000346	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK3—atherosclerosis	7.63e-05	0.000331	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—atherosclerosis	7.4e-05	0.000322	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—atherosclerosis	7.35e-05	0.000319	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	6.71e-05	0.000292	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLTP—atherosclerosis	6.31e-05	0.000274	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—atherosclerosis	5.58e-05	0.000242	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LTA4H—atherosclerosis	5.47e-05	0.000238	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG8—atherosclerosis	5.47e-05	0.000238	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—atherosclerosis	5.15e-05	0.000224	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG1—atherosclerosis	4.33e-05	0.000188	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LCAT—atherosclerosis	4.07e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FABP4—atherosclerosis	4.07e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOA4—atherosclerosis	3.99e-05	0.000173	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP7A1—atherosclerosis	3.92e-05	0.00017	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP27A1—atherosclerosis	3.62e-05	0.000157	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOA2—atherosclerosis	3.44e-05	0.000149	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	3.44e-05	0.000149	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALOX15—atherosclerosis	3.44e-05	0.000149	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	3.44e-05	0.000149	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG5—atherosclerosis	3.39e-05	0.000147	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LPA—atherosclerosis	3.28e-05	0.000142	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BGN—atherosclerosis	3.17e-05	0.000138	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOA5—atherosclerosis	3.14e-05	0.000137	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	3.03e-05	0.000131	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.92e-05	0.000127	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.62e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LIPC—atherosclerosis	2.6e-05	0.000113	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOC3—atherosclerosis	2.59e-05	0.000112	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LDLR—atherosclerosis	2.57e-05	0.000112	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CETP—atherosclerosis	2.51e-05	0.000109	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.41e-05	0.000105	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.27e-05	9.87e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.03e-05	8.8e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.74e-05	7.55e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOB—atherosclerosis	1.66e-05	7.23e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.62e-05	7.03e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LPL—atherosclerosis	1.59e-05	6.9e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX1—atherosclerosis	1.55e-05	6.74e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CD36—atherosclerosis	1.51e-05	6.56e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.43e-05	6.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARA—atherosclerosis	1.4e-05	6.1e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AGT—atherosclerosis	1.36e-05	5.91e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOE—atherosclerosis	1.33e-05	5.79e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAV1—atherosclerosis	1.32e-05	5.73e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOA1—atherosclerosis	1.32e-05	5.72e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.2e-05	5.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—atherosclerosis	1.16e-05	5.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—INS—atherosclerosis	1.14e-05	4.94e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—atherosclerosis	1.04e-05	4.53e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NOS3—atherosclerosis	9.98e-06	4.34e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—atherosclerosis	9.13e-06	3.97e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—atherosclerosis	4.59e-06	1.99e-05	CbGpPWpGaD
